Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Pamela Sheffels"'
Autor:
Kharasch, Evan D., Walker, Alysa, Whittington, Dale, Hoffer, Christine, Bedynek, Pamela Sheffels
Publikováno v:
In Drug and Alcohol Dependence 2009 101(3):158-168
Autor:
Dale Whittington, Amanda Crafford, D Ensign, Pamela Sheffels Bedynek, Thomas Kim, Amy London, Christine Hoffer, Evan D. Kharasch, Scott D. Campbell, Kristi Stubbert
Publikováno v:
Clinical Pharmacology & Therapeutics. 91:673-684
Mechanisms by which efavirenz diminishes methadone plasma concentrations are unknown. This investigation determined efavirenz influence on clinical methadone disposition and miosis, intravenous and oral alfentanil clearance (hepatic and intestinal cy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b36d87c7a79bc2e783f63f9d348ce8a6
https://doi.org/10.1038/clpt.2011.276
https://doi.org/10.1038/clpt.2011.276
Publikováno v:
Drug and Alcohol Dependence. 101:158-168
Methadone plasma concentrations are decreased by nelfinavir. Methadone clearance and the drug interactions have been attributed to CYP3A4, but actual mechanisms of methadone clearance and the nelfinavir interaction are unknown. We assessed nelfinavir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a57b85d2b0951c539d3bec865d1da35
https://doi.org/10.1016/j.drugalcdep.2008.12.009
https://doi.org/10.1016/j.drugalcdep.2008.12.009
Publikováno v:
Anesthesiology. 110:660-672
Background Methadone clearance is highly variable, and drug interactions are problematic. Both have been attributed to CYP3A, but actual mechanisms are unknown. Drug interactions can provide such mechanistic information. Ritonavir/indinavir, one of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33d7e029afd2b077d27c2bb6958f88cf
https://doi.org/10.1097/aln.0b013e3181986a9a
https://doi.org/10.1097/aln.0b013e3181986a9a
Autor:
D Ensign, Dale Whittington, Pamela Sheffels, Evan D. Kharasch, Nina Isoherranen, Kenneth T. Thummel, Christine Hoffer, Alysa Walker
Publikováno v:
Clinical Pharmacology & Therapeutics. 82:410-426
The hepatic and first-pass cytochrome P4503A (CYP3A) probe alfentanil (ALF) is also metabolized in vitro by CYP3A5. Human hepatic microsomal ALF metabolism is higher in livers with at least one CYP3A5*1 allele and higher CYP3A5 protein content, compa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53ce1c4130a65ff8b12cbf6b5bcd8a22
https://doi.org/10.1038/sj.clpt.6100237
https://doi.org/10.1038/sj.clpt.6100237
Autor:
H. Denny Liggitt, Dale Whittington, Sang B. Park, Jesara L. Schroeder, Pamela Sheffels, Evan D. Kharasch
Publikováno v:
Anesthesiology. 105:726-736
Background Methoxyflurane nephrotoxicity results from biotransformation; inorganic fluoride is a toxic metabolite. Concern exists about potential renal toxicity from volatile anesthetic defluorination, but many anesthetics increase fluoride concentra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4165ffbb15d793269d25429306b59406
https://doi.org/10.1097/00000542-200610000-00019
https://doi.org/10.1097/00000542-200610000-00019
Publikováno v:
The Journal of Clinical Pharmacology. 45:1187-1197
This investigation determined the ability of alfentanil miosis and single-point concentrations to detect various degrees of CYP3A inhibition. Results were compared with those for midazolam, an alternative CYP3A probe. Twelve volunteers were studied i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23f8a2a00569b7063f2f1cea4e008ce
https://doi.org/10.1177/0091270005280077
https://doi.org/10.1177/0091270005280077
Publikováno v:
Anesthesiology. 102:550-556
Background There is considerable unexplained interindividual variability in the clearance of alfentanil. Alfentanil undergoes extensive metabolism by cytochrome P4503A4 (CYP3A4). CYP3A5 is structurally similar to CYP3A4 and metabolizes most CYP3A4 su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b214e09fcb771a1e3e02b449dc805eac
https://doi.org/10.1097/00000542-200503000-00012
https://doi.org/10.1097/00000542-200503000-00012
Publikováno v:
The Journal of Clinical Pharmacology. 45:79-88
Cytochrome P4503A (CYP3A) and P-glycoprotein (P-gp) are major determinants of oral bioavailability. Development of in vivo probe(s), for both CYP3A and P-gp, which could be administered in combination, is a current goal. Nevertheless, there is consid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cadc6e47c4fed8b86223564f2c06274f
https://doi.org/10.1177/0091270004269705
https://doi.org/10.1177/0091270004269705
Publikováno v:
Clinical Pharmacology & Therapeutics. 76:452-466
Introduction Systemic clearance of intravenous (IV) alfentanil (ALF) is an in vivo probe for hepatic cytochrome P450 (CYP) 3A activity, miosis is a surrogate for plasma ALF concentrations, and IV ALF miosis is a noninvasive probe for hepatic CYP3A. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5501f2505a631d2cc51fdc849f5ec69
https://doi.org/10.1016/j.clpt.2004.07.006
https://doi.org/10.1016/j.clpt.2004.07.006